Reckitt expects 6% growth as deals multiply; IOM calls for counterfeit-preventing controls;

@FiercePharma: Sanofi plans to boost Lantus production in Ireland with a $59 million upgrade to Waterford site. More | Follow @FiercePharma

@EricPFierce: 2012 M&A was slow in biopharma as cos. choked down previous mega mergers. Execs may be ready to tango in 2013. Special Report | Follow @EricPFierce

@AlisonBFierce: The WHO granted PharmaJet's Stratis Needle-free Injector performance, quality and safety pre-qualification status. Release | Follow @AlisonBFierce

> Reckitt Benckiser expects up to 6% sales growth this year, as it continues its M&A drive. Report

> The Institute of Medicine called for a chain-of-custody approach to safeguarding the U.S. drug supply against counterfeits. Report

> Despite walking away from a full merger with Taro Pharmaceuticals ($TARO), India's Sun Pharma plans to continue to hold its Taro stock, an executive said. Report

> New research finds that a shorter, 18-month course of prostate cancer treatment works as well as the usual 36-month therapy. Report (sub. req.)

> Japanese drugmakers are scouting India for partners, aiming to sell Japanese-made drugs in India and vice-versa. Report

 @FierceMedDev: St. Jude recalls heart-plug component as FDA warns of fatal risk. News | Follow @FierceMedDev

 @MarkHFierce: Attorneys: JNJ knew of mesh problems before marketing. Article | Follow @MarkHFierce

 @DamianFierce: More regulatory struggles for St. Jude as it recalls a component of its Amplatzer heart plug. Story | Follow @DamianFierce

> J&J metal hip trial stirs up renewed call for 510(k) reform. Item

> Dako inks companion diagnostics deal with Pfizer. Article

Biotech News

 @FierceBiotech: In case you missed it: The 25 most influential people in biopharma today - 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: J&J, Pharmacyclics score 'breakthrough' coup with blockbuster hopeful ibrutinib. Article | Follow @JohnCFierce

@RyanMFierce: J&J's Alzheimer's R&D chief sticks by 'golden age' prediction after bapi bust. But where's the data? More | Follow @RyanMFierce

> Early-stage investor Lux targets biotech with new $245M VC fund. Story

> Ziopharm shares spike as PhIII palifosfamide reckoning looms. Story

Drug Delivery News

> Alnylam joins Spanish team to deliver successful RNAi. Story

> Genelux, Sloan-Kettering test delivery of mesothelioma drug. More

> Germany grants reimbursement for Delcath's chemo delivery tech. Item

> UCLA team snuffs cancer cells with nanoshell delivery. News

> Smiths Medical wins FDA clearance for 'smart' infusion pump. Report

And Finally... Lung cancer is likely to outstrip breast cancer as the primary cause of cancer death in European women. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.